Modernizing Old Medicine to Treat COVID-19

Michael Frank, Chairman and CEO of Revive Therapeutics, joins The Dales Report to talk about their filing for Phase 3 clinical trials to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More